Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04493203 · ClinicalTrials.gov registry record · Phase 2
Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma
A Phase 2 study, sponsored by Yana Najjar.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT04493203 is a Phase 2 study that has completed, run by Yana Najjar. The registered enrollment target is 31 participants.
The verdict
NCT04493203, a Phase 2 study, has completed, sponsored by Yana Najjar.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
This is Phase II trial of nivolumab plus axitinib for patients with unresectable stage III or IV melanoma who have progressed on prior anti-PD1 therapy with or without concomitant anti-CTLA4 therapy. Patients will receive treatment with nivolumab 480 mg intravenously every 4 weeks and axitinib 5 mg twice daily by mouth. Patients may continue both agents for up to two years if they do not experience disease progression or dose-limiting toxicities.
Interventions
- DRUG Nivolumab
- DRUG Axitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2020-12-18 |
| Est. Completion | 2025-04-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04493203
The ClinicalTrials.gov registry entry for NCT04493203 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yana Najjar, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT04493203 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04493203 about?
NCT04493203 is a clinical study titled "Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma". This is Phase II trial of nivolumab plus axitinib for patients with unresectable stage III or IV melanoma who have progressed on prior anti-PD1 therapy with or without concomitant anti-CTLA4 therapy. Patients will receive treatment with nivolumab 480 mg intravenously every 4 weeks and axitinib 5 mg ...
What is the current status of trial NCT04493203?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2020-12-18. Estimated completion is 2025-04-12.
What interventions are being tested in trial NCT04493203?
The interventions under investigation include: Nivolumab (DRUG), Axitinib (DRUG).
Who is sponsoring clinical trial NCT04493203?
This trial is sponsored by Yana Najjar, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.